1. Home
  2. FAX vs DNTH Comparison

FAX vs DNTH Comparison

Compare FAX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FAX
  • DNTH
  • Stock Information
  • Founded
  • FAX 1986
  • DNTH 2015
  • Country
  • FAX United States
  • DNTH United States
  • Employees
  • FAX N/A
  • DNTH N/A
  • Industry
  • FAX Investment Managers
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • FAX Finance
  • DNTH Health Care
  • Exchange
  • FAX Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • FAX 629.1M
  • DNTH 724.8M
  • IPO Year
  • FAX N/A
  • DNTH N/A
  • Fundamental
  • Price
  • FAX $15.85
  • DNTH $16.83
  • Analyst Decision
  • FAX
  • DNTH Strong Buy
  • Analyst Count
  • FAX 0
  • DNTH 8
  • Target Price
  • FAX N/A
  • DNTH $54.33
  • AVG Volume (30 Days)
  • FAX 833.6K
  • DNTH 363.8K
  • Earning Date
  • FAX 01-01-0001
  • DNTH 03-11-2025
  • Dividend Yield
  • FAX 12.09%
  • DNTH N/A
  • EPS Growth
  • FAX N/A
  • DNTH N/A
  • EPS
  • FAX N/A
  • DNTH N/A
  • Revenue
  • FAX N/A
  • DNTH $6,235,000.00
  • Revenue This Year
  • FAX N/A
  • DNTH N/A
  • Revenue Next Year
  • FAX N/A
  • DNTH N/A
  • P/E Ratio
  • FAX N/A
  • DNTH N/A
  • Revenue Growth
  • FAX N/A
  • DNTH 120.63
  • 52 Week Low
  • FAX $2.33
  • DNTH $16.44
  • 52 Week High
  • FAX $2.84
  • DNTH $32.27
  • Technical
  • Relative Strength Index (RSI)
  • FAX 53.44
  • DNTH 32.72
  • Support Level
  • FAX $15.53
  • DNTH $17.50
  • Resistance Level
  • FAX $16.13
  • DNTH $20.45
  • Average True Range (ATR)
  • FAX 0.16
  • DNTH 1.65
  • MACD
  • FAX -0.03
  • DNTH -0.31
  • Stochastic Oscillator
  • FAX 52.50
  • DNTH 6.36

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities, and others.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: